Illustration: Rae Cook/Axios
Novartis is continuing its deal spree, announcing plans Friday to buy venture-backed allergy biotech Excellergy for up to $2 billion.
Why it matters: The move strengthens Novartis' allergy franchise after a patent expiry last year opened the door to biosimilar competition.
